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Abstract
Introduction/objectives Polymyalgia rheumatica (PMR) is a common inflammatory disorder that is usually managed with oral
glucocorticoids, which although effective can cause significant adverse events. Support group survey data suggests length of
glucocorticoid treatment and managing side effects are key priority areas of management for patients. Recognising that not all
patients will access patient support organisations, our objective was to identify priorities for PMR management and research
among primary care PMR patients.
Method All adults aged ≥ 50 years registered with 150 English general practices who had a first read code for PMR in their
medical records in the preceding 3 years were mailed a self-completion questionnaire (n = 704). Survey items included questions
regarding patient priorities for PMR management (from a pre-defined list of 10 items) and suggestions for future research (8
items, plus a free-text option), which were developed in collaboration with PMRGCAuk.
Results Five hundred fifty patients responded (78%). The mean (SD) age was 74.1 (8.5) years and 361 (66%) were female.
Priority research areas were focused on how to better manage pain, stiffness and fatigue (431, 78%), improving the diagnosis of
PMR (393, 71%) and steroid management (342, 62%).
Conclusions This survey of PMR patients suggests that symptommanagement, early diagnosis and managingmedication are key
areas for patients for future research. Researchers and funding organisations should be aware of these priorities if we are to
generate research findings that are relevant to the widest range of stakeholders.
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Introduction
Polymyalgia rheumatica (PMR) is an inflammatory disorder
of older adults with a lifetime prevalence of 2.4% in women
and 1.7% in men [1]. It classically causes pain and stiffness in
the shoulders and hip girdles, which can lead to significant
levels of physical disability [2]. The mainstay of treatment is
oral glucocorticoids, which whilst effective are often required
for prolonged periods [3]. This places patients at potential risk
of adverse events and is a key concern for both patients [4] and
clinicians [5].
There is increasing evidence that there is a mismatch be-
tween what research patients want to see undertaken and re-
search being performed [6]. To address this disparity, the
James Lind Alliance Priority Setting Partnerships were creat-
ed, where partnerships of patients, carers and health profes-
sionals discussed and agreed on important priorities for treat-
ment and research in a range of health conditions, such as type
1 diabetes and stroke. An evaluation of these partnerships [6]
suggested that drug trials were preferred by researchers, and
non-drug treatments are preferred by patients, carers and
clinicians.
Involving patients in research is both best practice [7] and
increasingly becoming key to securing research funding with
many major funding bodies. However, reviews suggest that
although patients should play an active role in setting research
priorities, such participation remains the exception rather than
the rule [8]. The charity PMRGCAuk was established in 2010
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as an online community of patients with PMR or giant cell
arteritis. The charity had previously surveyed its membership
[9] to identify key priorities for PMR patients for information
and support together with areas they wished to see prioritised
for future research. Responses suggested that managing glu-
cocorticoids was the key priority for the majority of respon-
dents [9].
Patients who choose to join or access patient support
groups or charities may be different to the wider population
with a specific condition, with data from cancer survivors
suggesting that those accessing support groups were likely
to be female [10–12], younger [11, 13] and of Caucasian eth-
nicity [10, 12]. To investigate the broadest range of patient
experience, we sought to survey a primary care population
of people with PMR, using similar questions to those identi-
fied as important in the survey by PMRGCAuk [9]. Therefore,
the aim of this study was to examine patient priorities for
living with PMR and their priorities for PMR research within
a primary care population.
Materials and methods
Study design and population
A cross-sectional questionnaire study was developed to inves-
tigate the impact of PMR. Adults (age ≥ 50 years) with a first
read-coded diagnosis of PMR between January 1, 2010 and
January 1, 2013 were identified via an electronic search of
primary care records from 150 participating general practices
across England. The research lead from each practice screened
the list of identified patients and removed those in potentially
vulnerable groups (e.g. those with significant cognitive im-
pairment or a terminal diagnosis). Those eligible to participate
(n = 704) were mailed a study pack, including a questionnaire
and consent to participate; non-responders were sent a remind-
er postcard at 2 weeks and a repeat study pack at 4 weeks.
Ethical approval for the study was obtained from NRES-West
Midlands-Staffordshire (Ref 13/WM/0133).
Primary care records were used to establish disease dura-
tion, taken as time from date of diagnosis to date of question-
naire response. Other results in this article are derived from the
questionnaire data. This questionnaire included items relating
to sociodemographics (age, gender and personal circum-
stances), PMR characteristics (e.g. whether currently
experiencing symptoms) and health information-seeking be-
haviour (e.g. whether a doctor had provided written informa-
tion on PMR). Following collaborative work with the charity
PMRGCAuk, we used two questionnaire items related to pri-
orities around PMR which the charity had identified from
surveys of users of their telephone helpline [9]. The first item
presented ten aspects of living with PMR (e.g. managing pain,
see Table 2); participants were asked to select five as priorities.
Specifically, the question was BWhat in your opinion are the
most important aspects of living with PMR that people need
help with? This help might be information or support?^ The
second item presented nine areas for further PMR research
(e.g. diagnosis, see Table 3): participants were asked to select
any number of these as priorities.
Data analysis
Responders and non-responders to the questionnaire were
compared in terms of age and gender using a t test (equal
variances assumed) and a chi-squared test respectively, to
check for evidence of response bias. Other statistics calculated
were descriptive: the count and percentage of participants that
had selected each aspect of living with PMR or research area
as a priority were recorded.
The second questionnaire item regarding research priorities
included a free-text ‘other’ option. Responses to the ‘other’
option were categorised using content analysis. Content anal-
ysis is a systematic method for interpreting meaning in textual
data [14]. First, a single author (CM) read the free-text re-
sponses repeatedly in order to gain familiarity with them as
a whole. The words capturing the key concept in each re-
sponse were highlighted. During this process, codes emerged
that reflected the key concept in multiple responses. For ex-
ample, BWhy PMR develops and ways to prevent it^ and
BCausal factors - I blame mine on gall bladder removal^ were
both coded as BCauses of PMR^. The process was iterative; at
each stage, responses could be recoded and codes could be
relabelled, created or removed, until all responses were coded
to the author’s satisfaction.
A second author (SM) independently coded a random sam-
ple of 20 responses using the codes identified by CM. The two
authors then compared and discussed their choices. Although
there was disagreement on the coding of only one response,
the purpose of this exercise was not calculating a statistical
rate of agreement. Instead, the emphasis was on bringing the
authors’ different perspectives to bear on data interpretation.
Disagreement or uncertainty regarding the coding of individ-
ual responses was resolved by consensus to establish final
categories (Table 4). Responses that were illegible were coded
as Bdo not know^ or which had no clear connection to re-
search priorities were removed at this stage.
Results
Of the 704 patients that were mailed a questionnaire, 550
(78%) consented to participate (Fig. 1). Non-responders and
refusals were older than participants (mean (SD) 75.2 (9.2)
years versus 74.1 (SD 8.5), p = 0.17) and more often female
(n = 112 (73%) versus n = 361 (66%), p = 0.14), although
these differences were not statistically significant. Consistent
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Fig. 1 Study flow diagram
Table 1 Characteristics of n =
550 participants Variable N (%)
a
Sociodemographic
Gender Female 361 (66)
Age Mean (SD), 74.1 (8.5)
Employment status Employed 50 (9)
Retired 446 (81)
Unemployed/seeking work 2 (< 1)
Not working due to ill health 8 (1)
Housewife/husband 29 (5)
Other 12 (2)
Ethnicity White 539 (99)
Other 7 (1)
PMR characteristics
Current PMR symptoms Yes 374 (68)
No 152 (28)
Years since diagnosis Median (IQR), 2.0 (1.3, 2.6)
Health information-seeking behaviour
Received written information about PMR from their doctor Yes 273 (50)
No 261 (47)
Has internet access Yes 302 (55)
No 233 (42)
Used the internet to research PMR Yes 234 (43)
No 294 (53)
Contacted a patient support group Yes 10 (2)
No 527 (96)
Needs help reading documents from their doctor or pharmacy Always 15 (3)
Often 17 (3)
Sometimes 57 (10)
Rarely 53 (10)
Never 394 (72)
a Percentages may not add to 100 due to missing data
IQR, interquartile range; SD, standard deviation
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with other PMR studies, the majority of the sample was fe-
male (n = 361, 66%), with a mean age of 74.1 (SD 8.5) years
(Table 1). Median (IQR) time since diagnosis was 2.0 (1.3,
2.6) years. Sixty-eight percent (n = 374) of participants were
still experiencing PMR symptoms at the date of response.
Access to PMR-related information was mixed; 50% of par-
ticipants (n = 273) reported receiving written information
whilst 43% (n = 234) had used the Internet to research PMR.
Only 10 participants (2%) had contacted a patient support
group.
Priorities for living with PMR
Priorities selected as among the five most important aspects of
living with PMR can be seen in Table 2. Ninety-seven percent
of participants (n = 533) indicated at least one priority for liv-
ing with PMR, with the majority selecting five priorities (al-
though 22 selected more than 5 priorities, 58 selected fewer).
Managing stiffness (n = 415, 75%) and managing pain (n =
406, 74%) were most commonly identified as areas that re-
quired support. Ninety percent of participants (n = 497) select-
ed at least one of these two options. Other frequently selected
priorities were management of steroids and other medications
(n = 400, 73%), outlook for recovery (n = 376, 68%) and
things participants could do to help themselves (n = 355,
65%). Priorities did not differ by disease duration, using a
cutoff of greater or less than 2 years, including stiffness
(75% vs 76%), pain (73% vs 76%), steroid management
(73% vs 77%), outlook for recovery (72% vs 72%) and things
patients could do to help themselves (65% vs 63%).
Priorities for PMR research
Areas selected as priorities for PMR research, of which any
number could be selected, are displayed in Table 3. Ninety-
seven percent of participants (n = 535) indicated at least one
Table 2 Important aspects of
living with PMR. Participants
were asked to select five priorities
Selected as a priority, N (%)a
Aspect of living with PMR Males Females All
Managing stiffness 140 (75) 274 (76) 415 (75)
Managing pain 130 (70) 275 (76) 406 (74)
Management of steroids and other medications 140 (75) 259 (72) 400 (73)
Outlook for recovery 135 (73) 239 (66) 376 (68)
Things you can do to help yourself 118 (63) 235 (65) 355 (65)
Day to day activities 101 (54) 196 (54) 298 (54)
Non-medical treatments 24 (13) 80 (22) 105 (19)
Developing giant cell arteritis 37 (20) 67 (19) 104 (19)
Work 36 (19) 43 (12) 80 (15)
Contact with other people with the condition 22 (12) 52 (14) 74 (13)
Responses are presented in descending order of frequency
a Percentages include participants that did not select any priorities
Table 3 Priorities for PMR
research. Participants could select
any number of priorities
Selected as a priority, N (%)a
Area of PMR research Males Females All
Pain, stiffness and fatigue 142 (76) 288 (80) 431 (78)
Diagnosis 131 (70) 260 (72) 393 (71)
Steroid management 123 (66) 218 (60) 342 (62)
Things patients with PMR can do for their condition 107 (58) 227 (63) 335 (61)
Multiple health conditions 47 (25) 129 (36) 178 (32)
Alternative and complementary therapies 39 (21) 114 (32) 154 (28)
Developing giant cell arteritis 39 (21) 99 (27) 138 (25)
Role of health professionals 35 (19) 79 (22) 116 (21)
Other (see Table 4) 10 (5) 32 (9) 42 (8)
Responses are presented in descending order of frequency
a Percentages include participants that did not select any priorities
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research priority, with a median of 4 priorities (interquartile
range 3–5) being selected. Pain, stiffness and fatigue were the
research area most commonly prioritised (n = 431, 78%),
followed by diagnosis (n = 393, 71%), steroid management
(n = 342, 62%) and things patients could do themselves for
their condition (n = 335, 60%). The risk of developing giant
cell arteritis, a key concern for clinicians, was not frequently
prioritised by patients and was selected by only 138 (25%).
Eight percent of participants (n = 42) used the ‘other’ option to
describe research priorities beyond those pre-specified. Eight
of these responses were inadmissible: one was illegible, two
were Bdo not know^ and five had no clear connection to re-
search priorities. Using content analysis, 10 codes were iden-
tified (Table 4) from 35 priorities (one participant indicated
two distinct priorities). Treatment side effects (n = 7), causes
of PMR (n = 6) and delay in diagnosis (n = 6) were the most
frequently cited free-text priorities.
Discussion
PMR is commonly managed in primary care and can have
significant long-term impacts for patients. Understanding pa-
tient priorities around living with PMR and research priorities
is important to ensure research findings generated are relevant
to all stakeholders.
This is the first survey of primary care PMR patients to
investigate perspectives on the challenges of living with
PMR and their priorities for future research. These results
highlight that patients are concerned especially with managing
symptoms such as pain and stiffness and management of ste-
roids and that these are the areas that patients would prioritise
for future research. These findings are similar to previous
work surveying PMRGCAuk support group members [4]
which highlighted that concerns about steroids are an impor-
tant issue for patients. Developing giant cell arteritis, a key
concern for clinicians [15], was rarely considered as one of the
important aspects of living with PMR or as a research priority.
It is not clear to what extent this indicates a mismatch between
patient and clinical priorities, rather than a lack of patient
information regarding giant cell arteritis and its effects.
There are several strengths and weaknesses that need to be
considered when interpreting the results of this study. This was
a large cohort of PMR patients (550 patients) recruited from
across England and as such, the results are likely to be highly
generalisable. A limitation is that these patients were included
on the basis of a primary care diagnostic code for PMR, rather
than having been assessed in specialist services, although the
demographics of this population are similar to those seen in
both primary [16, 17] and secondary [18] care PMR cohorts.
By including patients with a range of disease durations (median
2 years), we may also have captured a different patient experi-
ence than those with recent onset disease, although our results
suggest that symptom management and medication remains
important issues for patients with a longer duration of disease.
In summary, a large primary care survey of people with
PMR suggests that management of symptoms such as pain,
stiffness and fatigue, diagnosis and managing steroids are key
research priorities for patients. Researchers and funding orga-
nisations should be aware of these priorities if we are to gen-
erate research findings that are relevant to the widest range of
stakeholders.
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Table 4 Priorities for PMR research described using the free text
‘other’ option and categorised using content analysis
Area of PMR research Selected as a priority, N (%)a
Side effects of treatment 7 (20)
Causes of PMR 6 (17)
Early diagnosis 6 (17)
Self-management of symptoms 5 (14)
Achieving remission 4 (11)
Availability of advice and information 2 (6)
Atypical presentation 2 (6)
Treatment pathways 1 (3)
Effect on ability to work 1 (3)
Testing for GCA by an ophthalmologist 1 (3)
a Percentage of admissible responses to the ‘other’ option
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